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ABSTRACT 
Objective: To investigate whether mentioning free or lower cost smoking cessation 
medication as a trigger for thinking about quitting is related to higher medication use, more 
quit attempts and quit success, and whether these associations are modified by education and 
income. 
Methods: Data were derived from the 2013 and 2014 surveys of the International Tobacco 
Control (ITC) Netherlands (n=1164) and United Kingdom (n=768) cohort. Logistic 
regression analyses were used to assess associations between mentioning in 2013 that 
free/lower cost smoking cessation medication was a trigger for thinking about quitting 
smoking and the use of medication, quit attempts and smoking cessation in 2014.  
Results: 37.0% of smokers in the UK and 24.9% of smokers in the Netherlands mentioned 
free/lower cost medication as a trigger for thinking about quitting. Smokers who mentioned 
this trigger were more likely to have used cessation medication during a quit attempt both in 
the UK (OR = 4.19, p < 0.001) and in the Netherlands (OR = 2.14, p = 0.033). The 
association between mentioning free/lower cost medication as a trigger for thinking about 
quitting and actual quit attempts was significant in the UK (OR = 1.45, p = 0.030), but not in 
the Netherlands (OR = 1.10, p = 0.587). There was no significant association with quit 
success. Associations did not differ across income and education groups.  
Conclusion: Free/lower cost smoking cessation medication may increase the use of cessation 
medication and stimulate quit attempts among smokers with low, moderate, and high 
education and income. 
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INTRODUCTION 
In Western countries, the proportion of smokers is not equally divided among low and high 
socioeconomic groups. [1-3] Individuals with lower education and income are more likely to 
smoke and smoke more cigarettes a day than higher educated and more affluent people. [4, 5] 
This disparity causes smoking to be the largest contributor to socioeconomic differences in 
health and mortality observed in Western countries. [6, 7] Although the proportion of people 
who smoke is generally declining, inequalities according to socioeconomic status (SES) have 
sustained or increased over time. [2, 3, 8-11] In the United kingdom (UK), 21% of 
individuals with no formal qualifications smoke compared to 9% of individuals with a 
degree. [12] In the Netherlands (NL), a comparable SES gap in smoking prevalence exists: 
28% of lower educated adults smoke compared to 19% of higher educated adults. [13] In 
order to reduce this socioeconomic gap, it is vital to develop methods and policies effective 
for smokers with a lower socioeconomic status.  
Having to pay for smoking cessation treatment like bupropion, varenicline or nicotine 
replacement therapy -from here on referred to as ‘cessation medication’- can be a barrier for 
seeking treatment, particularly for people on a low income. [14] More smokers use cessation 
medication when it is cost-free, [15] and this can substantially increase the number of long 
term quitters. [16] In a study based on data from the International Tobacco Control (ITC) 
Europe surveys, respondents with lower education and income mentioned the availability of 
free/lower cost medication more often as a trigger for thinking about quitting smoking than 
other education and income groups. [17] Still, mentioning free/lower cost medication as a 
trigger for thinking about quitting does not necessarily lead to more use of medication, nor to 
more quit attempts and a greater likelihood of quit success. Data from the ITC Four Country 
surveys [18] suggested that mentioning free/lower cost medication as a trigger to think about 
quitting was positively associated with making a quit attempt. Yet, it was not examined 
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whether this association was dependent on respondents’ income or education. Furthermore, it 
was not assessed whether free/lower cost medication as a trigger was associated with actual 
use of cessation medication and quit success.  
In the current study, the ITC data from the UK and the Netherlands is used to investigate SES 
differences in mentioning free/lower cost medication as a trigger to think about quitting 
smoking and quitting behaviour. The cultural and economic similarities of the UK and the 
Netherlands make it interesting to compare these two countries.  In both countries smokers 
have the opportunity to receive free/lower cost smoking cessation treatment. In the UK, the 
National Health Service provides smokers with free or subsidised cessation medication 
(dependent on smokers’ income) by trained practitioners in routine practice and via the stop-
smoking services; behavioural support can also be obtained free via the stop-smoking 
services for all. [19, 20] Stop smoking services vary across the UK but the standard model of 
treatment is an assessment before quitting which takes place about a week later, and then 
weekly sessions until four weeks after the quit date. [21] In the Netherlands, 
pharmacotherapy can be reimbursed once every year by the Dutch health insurance system 
only in combination with behavioural therapy, irrespective of treatment completion or 
outcome. There are possibilities for receiving behavioural therapy, such as the general 
practitioner, outpatient services, or independent healthcare providers registered in the Dutch 
quality register for scientifically proven effective smoking cessation treatment. Still, 
reimbursement applies only after patients have spent a mandatory deductible for general 
healthcare costs (at least 350 euro in 2013). 
The aim of this study is to investigate whether in the UK and the Netherlands free/lower cost 
cessation medication mentioned as a trigger for thinking about quitting is related to use of 
medication, quit attempts and quit success and whether these associations are modified by 
education and income. It is hypothesized that smokers who mentioned free or lower cost 
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medication as a trigger were more likely to make a quit attempt, to use cessation medication 
and had higher quit rates. Moreover, it is expected that this association is stronger for 
smokers with lower income and education than smokers with higher income and education, 
as the cost of cessation treatment has been mentioned as a barrier to quitting smoking by 
smokers with lower income and education. [22, 23] 
METHODS 
Data were used from the 2013 and 2014 surveys of the ITC Netherlands and UK cohorts. The 
ITC Project is a prospective cohort study of a representative sample of smokers and ex-
smokers in each country. [24] Survey data were collected by web (59%) and telephone (41%) 
for the UK and by web only for the Netherlands. Surveys were collected from February to 
September 2013 and from August to December 2014 in the UK, and from May to June 2013 
and from May to June 2014 in the Netherlands. All respondents were current smokers at time 
of enrolment. More details on the methods of the ITC data collection can be found in 
previous publications. [24, 25] Drop out between the two survey waves was 18% for the 
Netherlands and 30% for the UK. In the current study, participants were selected of 18 years 
and older who participated in both waves and who smoked at least monthly in the 2013 
survey. This formed a sample of n=1164 smokers from the Netherlands, and n=768 from the 
UK.  
Free/lower cost medication as a trigger for thinking about quitting 
The main independent variable of this study was whether respondents mentioned free/lower 
cost smoking cessation medication as a trigger for thinking about quitting. This is referred to 
as ‘free/lower cost medication as a trigger’ in the remainder of this paper. It was measured in 
the 2013 surveys with the following question: ‘In the past 6 months, has free, or lower cost, 
stop-smoking medication led you to think about quitting?’[17].  
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The question was part of a list with four policy triggers, of which each could be selected 
independently from the others by the respondent.  The other triggers (which were not the 
focus in this paper) were: the price of cigarettes, smoking restrictions in public places and 
warning labels on cigarette packages. Response options were: ‘not at all’, ‘somewhat’ and 
‘very much’. For the analyses, the response options were dichotomized: ‘not at all’ was 
classified as no trigger for thinking about quitting; ‘somewhat’ and ‘very much’ was 
classified as a positive trigger for thinking about quitting smoking.  
Use of smoking cessation medication  
Participants in both countries were asked in the 2014 surveys whether they had previously 
used smoking cessation medications. In the Netherlands, respondents were asked about 
medication use in the last year while in the UK, medication use during the last quit attempt 
was assessed. Therefore, these survey items were not entirely comparable. 
Quit attempts and quit success 
To measure quit attempts, participants were asked the following question in the 2014 survey: 
‘Have you made any attempts (successful or not) to stop smoking in the last year? 
Participants who responded affirmatively on this question were defined as having made a quit 
attempt. Successful quitters were defined as current smokers in 2013 who reported having 
made a quit attempt  and not  smoking at all or less than once a month in 2014. [26]  
Income and education 
Respondents from the Netherlands were asked about their monthly gross household income 
while UK respondents reported their annual gross household income. Response categories 
also differed between the two countries. The income variables were recoded into three 
categories based on tertiles in each country: defined as ‘low’ if income <€2 000 (NL) or <£15 
000 (UK), ‘moderate’ if between €2 000 and €3 000 (NL) or between £15 000 and £30 000 
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(UK) and ‘high’ if > €3 000 (NL) or >£30 000 (UK). Respondents had the option not to 
disclose their income. These responses were treated as missing values. The level of education 
for both countries was recoded into three groups: ‘low’ for none completed, elementary 
school and lower secondary education; ‘moderate’ for secondary vocational education and 
middle secondary education; and ‘high’ for upper secondary education, university and post-
graduate.  
Covariates 
Several covariates were used in the analyses, including gender and age (divided into four 
categories: 18-24 years, 25-39 years, 40-54 years, and 55 years and older). Nicotine 
dependence was measured by the Heaviness of Smoking Index (HSI). [27, 28] The HSI is a 
score ranging from 0-6 (low to high nicotine dependence) and is calculated based on both the 
number of cigarettes smoked per day and the time before smoking the first cigarette after 
waking up.  
Analyses  
IBM SPSS version 21.0 [29] was used to analyse the data. Cross-sectional and longitudinal 
weights were calculated using age and gender for each country separately. [24] Three 
multivariate logistic regression analyses were used to analyse the data. The associations were 
assessed between mentioning free/lower cost medication as a trigger to quit and (1) use of 
smoking cessation medication, (2) making a quit attempt and (3) smoking cessation one year 
later. Covariates in all analyses were gender, age, and HSI. To account for possible “time-in-
sample” effects where answers from respondents who have participated in multiple survey 
waves vary from newly recruited respondents, [30] analyses were adjusted for the 
respondents’ number of times they participated in the survey. [31] Two-way interactions 
between education and trigger and between income and trigger were included in the analyses. 
Due to between-country differences in data collection and survey items, analyses were 
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conducted separately for the Netherlands and the UK. As secondary analyses, the other three 
policy triggers (the price of cigarettes, smoking restrictions in public places and warning 
labels on cigarette packages) were added as independent variables in separate multivariate 
logistic regression analyses.  
 
RESULTS 
Demographics   
The socio-demographic characteristics of the respondents are presented in Table 1. The UK 
research sample had a higher percentage (53%) of high educated smokers than the 
Netherlands (25%) (p < 0.001). In the Netherlands, 30% of respondents did not report their 
household income, compared to 8% in the UK. Appendix 1 shows medication use, quit 
attempts and quit success for respondents who did and who did not disclose their income.  
Smokers in both countries had a comparable level of nicotine dependence (p = 0.448), with 
the largest group of respondents reporting an HSI between 2 and 4. Loss to follow up was 
higher among younger participants in both countries and higher among lighter smokers in the 
UK (Appendix 2).  
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Table 1. Characteristics of participants in the first wave in the UK and the Netherlands (2013). Weighted data. 
 United Kingdom 
(n = 768) 
The Netherlands  
(n = 1164) 
Between country 
differences 
 
Gender  
 Female (%) 
 
 
48.6 
 
 
49.3 
 
 
2 (1) = 0.08  
p = (0.777) 
 
Age  
 18-24 years (%) 
 25-39 years (%) 
 40-54 years (%) 
 55 years and older (%) 
 
 
11.9 
27.2 
33.4 
27.6 
 
 
12.8 
23.1 
33.4 
30.6 
 
 
2 (3) = 4.90  
(p = 0.179) 
 
Heaviness of Smoking Index 
 0-1 (%) 
 2-4 (%) 
 5-6 (%) 
 
 
27.5 
65.8 
6.7 
 
 
29.6 
63.0 
7.5 
 
 
2 (2) = 1.61  
(p = 0.448) 
 
Income level 
 Low (%) 
 Moderate (%)  
 High (%) 
 Not reported (%) 
 
 
28.5 
31.7 
32.0 
7.7 
 
 
22.0 
20.1 
27.8 
30.1 
 
 
2 (2) = 144.40  
(p < 0.001) 
 
Educational level 
 Low (%) 
 Moderate (%)  
 High (%) 
 
 
17.4 
30.1 
52.5 
 
 
29.2 
45.4 
25.4 
 
 
2 (2) = 146.59  
(p < 0.001) 
    
 
Free/lower cost medication as a trigger for thinking about quitting 
In 2013, free/lower cost medication was mentioned as a trigger for thinking about quitting by 
24.9% of the respondents in the Netherlands and 37.0% of the respondents in the UK (results 
not shown in table). When comparing income groups, free/lower cost medication as a trigger 
was mentioned in the Netherlands by 30.7% of low income smokers compared to 20.9% of 
moderate income smokers and 21.1% of high income smokers (2 (2) = 9.45, p = 0.009). In 
the UK, free/lower cost medication as a trigger was mentioned by 40.2%, 33.6% and 39.2% 
of low, moderate and high income groups respectively (2 (2) = 2.47, p = 0.290). When 
education groups were compared, in the Netherlands 28.8% of smokers with low education, 
25.7% of smokers with moderate education and 21.2% of smokers with high education 
mentioned free/lower cost medication as a trigger (2 (2) = 4.98, p = 0.083). In the UK, 
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38.8% of smokers with low education, 41.1% of smokers with moderate education, and 
34.1% smokers with high education mentioned free/lower cost medication as a trigger (2 (2) 
= 3.17, p = 0.205). 
Medication use 
In the Netherlands, 31.2% of smokers who made a quit attempt in the last year and mentioned 
free/lower cost medication as a trigger, used smoking cessation medication in the last year 
compared to 15.8% who did not report this trigger (p = 0.001, Figure 1 and Table 2). In the 
UK, the medication use in the group of respondents that mentioned free/lower cost 
medication as a trigger was 54.8% compared to 29.2% in the group that did not report the 
trigger (p < 0.001, Figure 2). Free/lower cost medication as a trigger was also positively 
associated with medication use in a multivariate analyses both in the UK (OR = 4.19, p < 
0.001) and in the Netherlands (OR = 2.14, p = 0.033) (Table 3). The multivariate analyses 
showed no significant interactions between free/lower cost medication as a trigger, 
medication use, and education and income groups. With the other policy triggers (smoking 
restrictions in public places, the price of cigarettes and warning labels on cigarette packages) 
added to the model, free/lower cost medication as a trigger was no longer significantly 
associated with medication use in the Netherlands (OR = 1.83, p = 0.113), but remained 
significant in the UK (OR = 4.26, p < 0.001) (results not shown in table).  
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Table 2. Medication use, quit attempts and quit success within the entire sample and within respondents who 
mentioned free/lower cost medication as a trigger (weighted data).  
 Entire sample Mentioned free/lower cost medication as a 
trigger 
 UK NL p-value UK NL p-value 
 
Medication use (%) 
 
39.8 
 
20.1 
 
<0.001 
 
54.8 
 
31.2 
 
<0.001 
 
Quit attempts (%) 
 
43.0 
 
32.7 
 
<0.001 
 
48.2 
 
36.2 
 
0.003 
 
Quit success (%) 
 
35.2 
 
28.5 
 
0.064 
 
34.1 
 
19.3 
 
0.014 
 
Table 3. Multivariate logistic regression analysesa showing associations between free/lower cost cessation 
medication as a trigger for thinking about quitting smoking and medication use, quit attempts, and quit success 
in the UK and the Netherlands (weighted data). 
 Medication usea  
OR (95% CI) 
 Quit attempts 
OR (95% CI) 
Quit successa 
OR (95% CI) 
 UK NL UK NL UK NL 
Gender 
 Female 
 Male 
 
0.67 (0.38 to 1.19) 
1.00 
 
0.70 (0.36 to 1.35) 
1.00 
 
1.04 (0.75 to 1.44) 
1.00 
 
0.79 (0.59 to 1.07) 
1.00 
 
1.28 (0.74 to 2.20) 
1.00 
 
1.95 (1.10 to 3.45)* 
1.00 
Age 
 18-24 years  
 25-39 years  
 40-54 years  
 55 years+ 
 
1.67 (0.61 to 4.58) 
0.97 (0.42 to 2.20) 
0.66 (0.28 to 1.52) 
1.00 
 
0.14 (0.03 to 0.71)* 
0.53 (0.22 to 1.26) 
1.21 (0.55 to 2.69) 
1.00 
 
2.34 (1.33 to 4.13)** 
1.89 (1.19 to 3.00)** 
1.27 (0.82 to 1.98) 
1.00 
 
1.18 (0.71 to 1.97) 
1.75 (1.16 to 2.65)** 
1.04 (0.70 to 1.54) 
1.00 
 
0.60 (0.23 to 1.54) 
0.78 (0.36 to 1.70) 
0.69 (0.32 to 1.52) 
1.00 
 
0.33 (0.10 to 1.06) 
0.95 (0.43 to 2.09) 
1.11 (0.52 to 2.38) 
1.00 
Heaviness of  
Smoking Index 
 
0.99 (0.83 to 1.19) 
 
1.38 (1.10 to 
1.72)** 
 
0.96 (0.86 to 1.07) 
 
0.88 (0.79 to 0.97)* 
 
0.85 (0.72 to 1.02) 
 
0.74 (0.61 to 0.90)** 
 
Trigger 
 Yes 
 No 
 
4.19 (2.33 to 7.53)*** 
1.00 
 
2.14 (1.07 to 4.29)* 
1.00 
 
1.45 (1.04 to 2.02) * 
1.00 
 
1.10 (0.78 to 1.56) 
1.00 
 
0.99 (0.58 to 1.68) 
1.00 
 
0.58 (0.28 to 1.20) 
1.00 
Income level 
 Low  
 Moderate  
 High  
 
 
1.47 (0.70 to 3.08) 
0.64 (0.32 to 1.27) 
1.00 
 
1.68 (0.77 to 3.67) 
2.00 (0.89 to 4.46) 
1.00 
 
0.76 (0.50 to 1.16) 
0.74 (0.50 to 1.09) 
1.00 
 
1.12 (0.78 to 1.61) 
0.74 (0.51 to 1.07) 
1.00 
 
0.65 (0.32 to 1.32) 
0.62 (0.33 to 1.18) 
1.00 
 
0.45 (0.23 to 0.90)* 
0.43 (0.21 to 0.88)* 
1.00 
Education level 
 Low  
 Moderate  
 High  
 
 
2.17 (0.87 to 5.46) 
0.49 (0.24 to 0.97)* 
1.00 
 
0.49 (0.19 to 1.22) 
0.71 (0.32 to 1.56)  
1.00 
 
0.85 (0.52 to 1.38) 
0.56 (0.38 to 0.82)** 
1.00 
 
0.78 (0.51 to 1.20) 
0.84 (0.59 to 1.21) 
1.00 
 
0.70 (0.29 to 1.68) 
0.53 (0.27 to 1.02) 
1.00 
 
1.30 (0.56 to 2.98) 
1.11 (0.57 to 2.19) 
1.00 
Time-in-sample 0.85 (0.76 to 0.93)* 0.93 (0.80 to1.07) 0.96 (0.91 to 1.02) 0.98 (0.91 to 1.05) 
 
1.03 (0.94 to1.13) 1.12 (0.98 to 1.28) 
a Only participants who made a quit attempt in the last year 
UK = United Kingdom, NL = Netherlands, Trigger = participant mentioned free/lower cost medication as a trigger for thinking about 
quitting smoking 
*p < 0.05 
** p < 0.01 
*** p < 0.001 
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Quit attempts  
A bivariate analysis showed that 36.2% of respondents in the Netherlands who mentioned 
free/lower cost medication as a trigger made at least one quit attempt between 2013 and 2014 
compared to 31.5% who did not report this trigger (p = 0.133, see Figure 1). In the UK, these 
numbers were 48.2% versus 39.9% (p = 0.025, see Figure 2). The multivariate analyses 
showed that in the UK, respondents who mentioned free/lower cost medication as a trigger 
had a higher rate of quit attempts within the next year than those who did not report this 
trigger (OR = 1.45, p = 0.030), but this association was not found in the Netherlands (OR = 
1.10, p = 0.587, see Table 3). There were no significant interactions between free/lower cost 
medication as a trigger and education and income levels for quit attempts in the multivariate 
analyses. When other policy triggers were added to the analysis as independent variables, 
free/lower cost medication as a trigger was no longer significantly associated with quit 
attempts in the UK (OR = 1.14, p = 0.489), and remained non-significant in the Netherlands. 
Quit success 
Within the group of smokers who made a quit attempt, in the Netherlands 19.3% of 
respondents who mentioned medication as a trigger quit smoking successfully compared to 
32.0% who did not report this trigger (p = 0.012, Figure 1). In the UK, this was 34.1% versus 
35.9% (p = 0.728, Figure 2). The multivariate analyses showed no significant association 
between free/lower cost medication as a trigger for thinking about quitting smoking and quit 
success (Table 3). The analyses showed no significant interactions between free/lower cost 
medication as a trigger and quit success for different income and education levels. With the 
other three policy triggers added to the model, the association between free/lower cost 
medication as a trigger and quit success remained not significant.  
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DISCUSSION 
The aim of this study was to investigate whether mentioning free/lower cost medication as a 
trigger to think about quitting smoking was related to the use of cessation medication, quit 
attempts and quit success in the UK and the Netherlands, and whether these associations were 
modified by education and income. The results showed a positive association between 
mentioning free/lower cost medication as a trigger and the use of smoking cessation 
medication in both the UK and the Netherlands. This finding is in line with previous research, 
which showed that financial coverage leads to an increased utilization of smoking cessation 
medication. [15] 
Smokers who mentioned free/lower cost medication as a trigger for thinking about quitting 
smoking were more likely to have made a quit attempt a year later in the UK, but not in the 
Netherlands. The association between free/lower cost medication as a trigger to quit smoking 
and quit attempts has also been demonstrated in Canada, the USA and Australia. [18] The 
finding that there was no significant association between free/lower cost medication as a 
trigger and quit attempts in the Netherlands may result from the difference in availability of 
free/lower cost medication compared to the UK. The UK’s stop smoking services and health 
professionals provide subsidised medications for any smokers who want to quit, while in the 
Netherlands health insurance reimbursement for smoking cessation medication is only 
available after a mandatory deductible amount is first spent. Not being able to receive free 
medication could demotivate smokers to follow through with their intended quit attempt. [22, 
32]  
Smokers who mentioned free/lower cost medication as a trigger were not more likely to quit 
successfully which emphasizes that it is a large step from contemplating quitting to actually 
achieving this goal. Firstly, there may be barriers preventing smokers to start and sustain a 
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quit attempt with medication, such as availability of free medication, self-efficacy and 
motivation. [32-35] Likewise, many factors can influence whether a quit attempt leads to 
successful quitting. [36] The current study did not investigate which hindering or promoting 
factors influence the relation between free/lower cost medication as a trigger and quit 
success, but further research focussing on this question could give important insights in how 
to achieve quit success in smokers who are triggered to think about quitting by free 
medication.  
When the other policy triggers (smoking restrictions in public places, the price of cigarettes 
and warning labels on cigarette packages) were added to the analyses, the associations 
between free/lower cost medication as a trigger and the use of medication in the Netherlands, 
and quit attempts in the UK were no longer significant. However, the association between 
free/lower cost medication as a trigger and the use of smoking cessation medication in the 
UK remained significant after correcting for the other policy triggers, which makes this the 
most robust finding of this study. 
Another aim of this study was to investigate whether the income and education level of 
smokers influenced the association between mentioning free/lower cost medication as a 
trigger to quit smoking and use of cessation medications, quit attempts, and quit success. 
Contrary to our hypothesis, the results showed that this association was not influenced by 
education or income level. This may mean that smokers with a lower SES as well as smokers 
with a higher SES who are triggered to think about quitting smoking by free cessation 
medication are equally likely to use medication, to make a quit attempt, and potentially be 
successful in this attempt.  
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Limitations 
This study has some limitations that should be taken into consideration. The validity of the 
survey question about whether respondents considered free/lower cost medication as a trigger 
to quit smoking was assumed but not investigated in this study. Loss to follow-up was higher 
among younger respondents in both countries, which could have influenced the results since 
research has shown that young adults were more likely to try quitting smoking, were more 
successful in quitting and were less likely to use cessation medication than older adults. [37, 
38] The UK and Netherlands data were not completely comparable since there were 
significant differences in income and education levels and differences in measuring the use of 
smoking cessation medication. In the UK, medication use was measured for the last quit 
attempt while in the Netherlands it was measured for the last year. Therefore, the use of 
cessation medication may have predated the (by free medication triggered) thought about 
quitting smoking. In the UK, the lower education group was under represented. In the 
Netherlands, a large portion of the respondents did not disclose their income, which could 
have influenced the results if income was not equally distributed among these non-
responders. Additionally, in the Netherlands, data were collected by web questionnaires only 
and in the UK also by telephone. This difference in data collection could have affected survey 
outcomes but was expected to be of minor influence on the results of this study. [39] 
 
Practical implications  
This study found that smokers who considered free/lower cost medication as a trigger to quit 
smoking were more likely to actually use cessation medication, and that smokers from the 
UK were more likely to have attempted to quit smoking. To promote smoking cessation it 
may therefore be beneficial to raise awareness of the availability of free cessation medication, 
for example through mass media campaigns or healthcare providers.  
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The finding that the association between mentioning free/lower cost medication as a trigger 
for thinking about quitting smoking and actual quit attempts was not influenced by education 
or income level suggests that free medication can motivate a large part of the smoking 
population to quit, and that this effect is not restricted to particular socioeconomic groups. 
Yet, since free medication is mentioned more often as a trigger to quit smoking by lower 
income smokers in the Netherlands in the current study and in previous research also in the 
UK, Ireland and Germany, [17] free medication may be an important strategy to decrease the 
socioeconomic gap in smoking.   
Conclusion 
Considering free/lower cost smoking cessation medication as a trigger for thinking about 
quitting smoking could, irrespective of smokers’ income or education, be positively 
associated with quit attempts and may promote the use of cessation medication during this 
attempt. Therefore, making cessation medication freely accessible to smokers may be an 
important strategy  to decrease smoking in the population. 
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What this paper adds 
• In previous research, free/lower cost smoking cessation treatment has shown to be a 
trigger for thinking about quitting smoking for smokers with a lower education and 
income and this trigger was positively associated with making a quit attempt.  
• It has been unclear whether mentioning free/lower cost medication as a trigger for 
thinking about quitting was associated with actual use of cessation medication and 
quit success and whether this association was dependent on smokers’ income or 
education.  
• This study showed that mentioning free/lower cost medication as a trigger for 
thinking about quitting smoking was positively associated with quit attempts in the 
UK and promoted the use of cessation medication  in both the Netherlands and the 
UK, irrespective of smokers’ education or income.  
Acknowledgements 
Parts of this paper appeared in the thesis of co-author Karin Hummel, which was also 
published as an article (see reference 17). We thank the ITC Project and the Propel Centre for 
Population Health Impact (University of Waterloo) for their contribution in project 
management, survey development and data cleaning. 
Funding 
The ITC Netherlands Surveys were supported by grants from the Netherlands Organisation 
for Health Research and Development (ZonMw #200130002). The ITC UK Project was 
supported by grants R01 CA 100362 and P01 CA138389 from the National Cancer Institute 
of the USA, Canadian Institutes of Health Research (115016). 
Contributor statement 
FAB and GEN conducted the statistical analyses together and FAB drafted the manuscript. 
 18 
All authors contributed to the writing of the manuscript and revised and approved the final 
manuscript.  
LITERATURE 
1 Reid JL, Hammond D, Boudreau C, et al. Socioeconomic disparities in quit intentions, quit attempts, 
and smoking abstinence among smokers in four western countries: findings from the International 
Tobacco Control Four Country Survey. Nicotine & tobacco research : official journal of the Society for 
Research on Nicotine and Tobacco 2010;12 Suppl:S20-33. 
2 Hiscock R, Bauld L, Amos A, et al. Smoking and socioeconomic status in England: the rise of the 
never smoker and the disadvantaged smoker. J Public Health (Oxf) 2012;34(3):390-396. 
3 Nagelhout GE, de Korte-de Boer D, Kunst AE, et al. Trends in socioeconomic inequalities in smoking 
prevalence, consumption, initiation, and cessation between 2001 and 2008 in the Netherlands. 
Findings from a national population survey. BMC Public Health 2012;12(1):1-9. 
4 Huisman M, Kunst AE, Mackenbach JP. Inequalities in the prevalence of smoking in the European 
Union: comparing education and income. Prev Med 2005;40(6):756-764. 
5 Schaap MM, Kunst AE. Monitoring of socio-economic inequalities in smoking: Learning from the 
experiences of recent scientific studies. Public Health 2009;123(2):103-109. 
6 Siahpush M, English D, Powles J. The contribution of smoking to socioeconomic differentials in 
mortality: results from the Melbourne Collaborative Cohort Study, Australia. J Epidemiol Community 
Health 2006;60(12):1077-1079. 
7 Jha P, Peto R, Zatonski W, et al. Social inequalities in male mortality, and in male mortality from 
smoking: indirect estimation from national death rates in England and Wales, Poland, and North 
America. The Lancet 2006;368(9533):367-370. 
8 Giskes K, Kunst AE, Benach J, et al. Trends in smoking behaviour between 1985 and 2000 in nine 
European countries by education. J Epidemiol Community Health 2005;59(5):395-401. 
9 Gielkens-Sijstermans CM, Mommers MA, Hoogenveen RT, et al. Reduction of smoking in Dutch 
adolescents over the past decade and its health gains: a repeated cross-sectional study. Eur J Public 
Health 2010;20(2):146-150. 
10 Harper S, Lynch J. Trends in socioeconomic inequalities in adult health behaviors among US 
states, 1990–2004. Public Health Rep 2007;122(2):177-189. 
11 Federico B, Costa G, Kunst AE. Educational inequalities in initiation, cessation, and prevalence of 
smoking among 3 Italian birth cohorts. Am J Public Health 2007;97(5):838-845. 
12 Office for National Statistics. Dataset: Smoking habits in the UK and its constituent countries.  
2016. 
13 Verdurmen J, Monshouwer K, Van Laar M, et al. Factsheet Continu Onderzoek Rookgewoonten 
2013. Utrecht: Trimbos-instituut 2014. 
14 Roddy E, Antoniak M, Britton J, et al. Barriers and motivators to gaining access to smoking 
cessation services amongst deprived smokers – a qualitative study. BMC Health Serv Res 
2006;6(1):147. 
15 Van den Brand FA, Nagelhout GE, Reda AA, et al. Healthcare financing systems for increasing the 
use of tobacco dependence treatment. Cochrane Database of Systematic Reviews 2017(9). 
16 Kaper J, Wagena EJ, Willemsen MC, et al. Reimbursement for smoking cessation treatment may 
double the abstinence rate: results of a randomized trial. Addiction 2005;100(7):1012-1020. 
17 Hummel K, Nagelhout GE, Willemsen MC, et al. Trends and socioeconomic differences in policy 
triggers for thinking about quitting smoking: Findings from the International Tobacco Control (ITC) 
Europe Surveys. Drug Alcohol Depend 2015;155:154-162. 
 19 
18 Kasza KA, Hyland AJ, Borland R, et al. Cross-country comparison of smokers' reasons for thinking 
about quitting over time: findings from the International Tobacco Control Four Country Survey (ITC-
4C), 2002-2015. Tob Control 2016. 
19 Bauld L, Bell K, McCullough L, et al. The effectiveness of NHS smoking cessation services: a 
systematic review. Journal of Public Health 2010;32(1):71-82. 
20 NHS. : National Health Service:NHS Smokefree website. 
21 NCSCT. Standard treatment programme. A guide to providing behavioural support for smoking 
cessation London: National Centre for Smoking Cessation and Training 2014. 
22 Rosenthal L, Carroll-Scott A, Earnshaw VA, et al. Targeting cessation: Understanding barriers and 
motivations to quitting among urban adult daily tobacco smokers. Addict Behav 2013;38(3):1639-
1642. 
23 Bryant J, Bonevski B, Paul C, et al. Developing cessation interventions for the social and 
community service setting: A qualitative study of barriers to quitting among disadvantaged 
Australian smokers. BMC Public Health 2011;11(1):493. 
24 Thompson ME, Fong GT, Hammond D, et al. Methods of the International Tobacco Control (ITC) 
Four Country Survey. Tob Control 2006;15(suppl 3):iii12-iii18. 
25 Zethof D, Nagelhout GE, de Rooij M, et al. Attrition analysed in five waves of a longitudinal yearly 
survey of smokers: findings from the ITC Netherlands survey. Eur J Public Health 2016;26(4):693-699. 
26 Hyland A, Borland R, Li Q, et al. Individual-level predictors of cessation behaviours among 
participants in the International Tobacco Control (ITC) Four Country Survey. Tob Control 
2006;15(suppl 3):iii83-iii94. 
27 Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a 
revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86(9):1119-1127. 
28 Heatherton TF, Kozlowski LT, Frecker RC, et al. Measuring the Heaviness of Smoking: using self-
reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict 
1989;84(7):791-799. 
29 IBM Corp. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp. 2012. 
30 Thompson ME. Using Longitudinal Complex Survey Data. Annual Review of Statistics and Its 
Application 2015;2(1):305-320. 
31 Driezen P, Thompson M. Comparing policy measures across multiple ITC countries: Adjusting for 
time-in-sample. University of Waterloo 2011. 
32 Smith AL, Carter SM, Chapman S, et al. Why do smokers try to quit without medication or 
counselling? A qualitative study with ex-smokers. BMJ Open 2015;5(4):e007301. 
33 Jardin BF, Cropsey KL, Wahlquist AE, et al. Evaluating the effect of access to free medication to 
quit smoking: a clinical trial testing the role of motivation. nicotine & tobacco research 2014:ntu025. 
34 Twyman L, Bonevski B, Paul C, et al. Perceived barriers to smoking cessation in selected 
vulnerable groups: a systematic review of the qualitative and quantitative literature. BMJ Open 
2014;4(12):e006414. 
35 Gwaltney CJ, Metrik J, Kahler CW, et al. Self-efficacy and smoking cessation: a meta-analysis. 
Psychol Addict Behav 2009;23(1):56-66. 
36 Vangeli E, Stapleton J, Smit ES, et al. Predictors of attempts to stop smoking and their success in 
adult general population samples: a systematic review. Addiction 2011;106(12):2110-2121. 
37 Messer K, Trinidad DR, Al-Delaimy WK, et al. Smoking Cessation Rates in the United States: A 
Comparison of Young Adult and Older Smokers. Am J Public Health 2008;98(2):317-322. 
38 Curry SJ, Sporer AK, Pugach O, et al. Use of Tobacco Cessation Treatments Among Young Adult 
Smokers: 2005 National Health Interview Survey. Am J Public Health 2007;97(8):1464-1469. 
39 Nagelhout GE, Willemsen MC, Thompson ME, et al. Is web interviewing a good alternative to 
telephone interviewing? Findings from the International Tobacco Control (ITC) Netherlands Survey. 
BMC Public Health 2010;10(1):351. 
 
 20 
APPENDIX 1 
Proportion of smokers from the Netherlands and the UK who made a quit attempt, used medications and who 
quit successfully for respondents with different income levels and respondents who did not report their income 
(weighted data). 
 Income level   
 Low Moderate High Not reported* p-value 
 
Quit attempt (%) 
    UK 
    NL 
 
Used medication (%) 
    UK 
    NL 
    
Quit success (%) 
    UK 
    NL 
    
 
 
37.4 
36.0 
 
 
50.6 
26.3 
 
 
31.2 
21.3 
 
 
 
38.2 
29.6 
 
 
31.5 
23.3 
 
 
27.2 
21.9 
 
 
 
50.0 
36.2 
 
 
39.5 
15.4 
 
 
41.9 
41.5 
 
 
 
50.0 
27.6 
 
 
37.9 
18.6 
 
 
41.4 
23.5 
 
 
0.012 
0.037 
 
 
0.085 
0.214 
 
 
0.107 
0.002 
* In the UK 7.7% did not report their income, in the Netherlands 30.1% 
 
APPENDIX 2 
Baseline characteristics of respondents included in the analysis and respondents lost to follow-up for the 
Netherlands and the UK. 
 United Kingdom   The Netherlands    
 Included in  
analysis  
(n = 768) 
Lost to  
follow-up  
(n = 335) 
p-value Included in  
analysis 
(n = 1164) 
Lost to  
follow-up  
(n = 256) 
p-value 
 
Gender  
   Female (%) 
 
 
52.6 
 
 
47.2 
 
 
0.102 
 
 
49.0 
 
 
45.3 
 
 
0.301 
 
Age  
   18-24 years (%) 
   25-39 years (%) 
   40-54 years (%) 
   55+ years (%) 
 
 
3.8 
21.9 
42.2 
32.2 
 
 
9.6 
30.1 
36.1 
24.2 
 
 
<0.001 
 
 
17.9 
27.8 
30.7 
23.6 
 
 
23.4 
36.3 
28.9 
11.3 
 
 
<0.001 
 
Heaviness of Smoking Index 
   0-1 (%) 
   2-4 (%) 
   5-6 (%) 
 
 
27.0 
65.4 
7.5 
 
 
36.3 
57.4 
6.3 
 
 
0.011 
 
 
31.1 
62.2 
6.7 
 
 
27.2 
69.0 
3.8 
 
 
0.075 
 
 
Income level 
   Low (%) 
   Moderate (%)  
   High (%) 
   Not reported (%) 
 
 
31.0 
31.1 
29.9 
7.9 
 
 
32.2 
28.7 
31.3 
7.8 
 
 
0.863 
 
 
21.4 
18.9 
29.2 
30.5 
 
 
 
19.1 
21.9 
27.7 
31.2 
 
 
0.646 
 
Educational level 
   Low (%) 
   Moderate (%)  
   High (%) 
 
 
21.4 
27.2 
51.5 
 
 
16.6 
24.4 
59.0 
 
 
0.054 
 
 
26.3 
46.9 
26.7 
 
 
 
 
26.0 
49.2 
24.8 
 
 
0.770 
 
